To systematically screen and verify the active components in the Dong ethnic medicine Lengyuxiao Tang (LYXT; Semen Pharbitidis, Verbena officinalis L., and Zingiber officinale Roscoe) for treating fever and cough, this scheme established a methodology process integrating network pharmacology prediction and experimental verification. Firstly, using the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), with an oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 as criteria, the key active components of LYXT were screened, and the related targets for fever and cough were collected from multiple disease databases. Subsequently, the "component-target-disease" interaction network was constructed, and, through topological analysis and gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment, the core action targets (CYP3A4, POR) and key signaling pathways (MAPK pathway) were identified. Molecular docking technology was used to verify the binding ability of key components to core targets. Finally, a chronic bronchitis mouse model was established by intranasal instillation of lipopolysaccharide (LPS), and the in vivo anti-inflammatory efficacy of the predicted main active components was verified. The results showed that components such as β-carotene and saparenol, screened by network pharmacology, exhibited varying degrees of anti-inflammatory effects in animal experiments, and their mechanisms may involve inhibition of the MAPK/p38 signaling pathway. This scheme provides a repeatable example for the screening and mechanism research of active components in traditional ethnic medicines.
Traumatic brain injury (TBI) can cause persistent cognitive impairment accompanied by neuronal and synaptic damage. Astragaloside IV (AS-IV) has neuroprotective properties, but the signaling processes associated with its effects after TBI remain incompletely understood. Adult male mice underwent controlled cortical impact and received intraperitoneal AS-IV during a 28-day post-injury period, with GM1 included as a positive control. Behavioral assessments, immunofluorescence, Golgi-Cox staining, transmission electron microscopy, and immunoblotting were combined with NMDAR antagonist co-treatment and exploratory docking, molecular dynamics, and cellular thermal shift analyses. AS-IV treatment improved cognitive performance and was associated with preservation of dendritic and synaptic structure, increased NMDAR subunit expression, and changes in ERK1/2, CaMKII, and CREB phosphorylation and synapse-associated proteins. The 40 mg/kg dose showed greater effects than 80 mg/kg for several outcomes. Co-treatment with MK-801 or TCN-201 attenuated multiple AS-IV-associated effects, supporting involvement of NMDAR-related signaling. Computational predictions and NMDAR2A thermal stabilization were consistent with possible receptor engagement but did not establish direct binding, binding affinity, or receptor activation. Collectively, these findings suggest that modulation of NMDAR-related signaling alterations may contribute to the cognitive and synaptic structural and molecular effects associated with AS-IV after TBI. However, the present data do not establish direct NMDAR binding or activation, in vivo target occupancy, or NMDAR as the exclusive or primary molecular target of AS-IV.